Company profile

IRONWOOD PHARMACEUTICALS INC

NASDAQ:IRWDBiotechnology: Pharmaceutical Preparations

Drug pipeline (4)

Asset	Stage	Revenue	Trials	Status
DUZALLO	approved	—	1	approved
ZURAMPIC	approved	—	1	approved
LINACLOTIDE	phase4	—	14	completed, terminated
RECANACLOTIDE	phase2	—	2	completed, terminated

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (25)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT05740007	phase2	terminated	2023-03-28	2025-01-23	Ironwood Pharmaceuticals, Inc.	A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome
NCT03226899	phase4	terminated	2017-07-19	2019-02-25	Ironwood Pharmaceuticals, Inc.	A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment
NCT03931785	phase2	completed	2019-05-01	2020-02-26	Ironwood Pharmaceuticals, Inc.	A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome
NCT05362695	phase1	completed	2022-05-17	2022-06-30	Ironwood Pharmaceuticals, Inc.	A Study of Multiple-ascending Doses of IW-3300 in Healthy Subjects
NCT05188261	phase1	completed	2022-01-18	2022-03-09	Ironwood Pharmaceuticals, Inc.	A Study of Single Ascending Doses of IW-3300 in Healthy Volunteers

FDA applications (2)

Application

Approved

Type

Applicant

Products

NDA 209203

2017-08-18

NDA

IRONWOOD PHARMACEUTICALS INC

NDA 207988

2015-12-22

NDA

IRONWOOD PHARMACEUTICALS INC